rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures
rhBMP-2 Versus Vivigen, a Novel Cellular Allograft, in Lumbar Fusion Procedures: a Prospective Randomized Controlled Study
Sponsor: Virtua Health, Inc.
Terminated
PI left the institution
Other terminated trials from Virtua Health, Inc.
- Primary Osteoarthritis of Knee Nos · Phase NA · Jul 2022
- Deformity of Spine · Phase PHASE4 · Dec 2019
More terminations from Virtua Health, Inc.
Listed as NCT03527966, this PHASE4 trial focuses on Lumbar Spine Degeneration and remains terminated or withdrawn. Sponsored by Virtua Health, Inc., it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2022 — Mar 2022 [monthly]
Terminated PHASE4
-
Jan 2021 — Jan 2022 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Terminated PHASE4
-
May 2019 — Sep 2019 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Sep 2018 — May 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE4
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Virtua Health, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .